Advertisement

Nierenzellcarcinom

  • Jens Atzpodien
  • Tatjana Patzelt
  • Martina Reitz
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Mit 85% ist das Nierenzellcarcinom (Hypernephrom, Grawitz-Tumor) der häufigste bösartige Tumor der Niere. Der überwiegende Anteil der malignen Nierentumoren sind Adenocarcinome (85%), der Rest besteht aus Nierenbeckencarcinomen (7–8%), dem Nephroblastom bzw. Wilms-Tumor (5–6%) und anderen Histologien (Tab. 1). Das mittlere Manifestationsalter der Patienten mit Nierenzellcarcinom liegt zwischen 50 und 70 Jahren. Jährlich treten in Europa sowie in den Vereinigten Staaten jeweils 30.000 Neuerkrankungen mit einer Inzidenz von 7–8/100.000 und einer zu erwartenden Todesrate von jeweils bis zu 12.000 Patienten pro Jahr auf (Landis et al. 1998, SCI AM: Fact sheet 1996). Für die Industriestaaten wird eine Zunahme der Inzidenzrate berichtet; die höchste Inzidenz besteht in Nordamerika und Skandinavien (Whitmore Jr. 1989). Männer erkranken doppelt so häufig als Frauen. Ein Drittel der Patienten weist bei Diagnosestellung bereits Metastasen auf. Die 5-Jahres-Überlebensrate der Patienten mit metastasiertem Nierenzellcarcinom beträgt < 5%; eine standardisierte Behandlung konnte bisher nicht etabliert werden (Motzer et al. 1996, Savage 1995).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Agarwala SS, Bahnson, RR, Wilson JW, Szumowski J, Ernstoff, MS (1995) Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study. Am J Clin Oncol 18: 211–215.Google Scholar
  2. [2]
    Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U (1999) Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 19: 3841–3846.PubMedGoogle Scholar
  3. [3]
    Atzpodien J, Kirchner H, Bergmann L (1999) 13 cis-retinoic acid, IFN-alpha, IL-2 and chemotherapy in advanced renal cell carcinoma: Results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Immunotherapy Group (DGCIN). Proc Am Soc Clin Oncol: 19.Google Scholar
  4. [4]
    Atzpodien J, Kirchner H, Duensing S, Lopez HE, Franzke A, Buer J, Probst M, Anton P, Poliwoda H (1995a) Biochemotherapy of advanced metastatic renal-cell carcinoma: Results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174–177.PubMedGoogle Scholar
  5. [5]
    Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S, Ganser A (1997) Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proc Am Soc Clin Oncol.Google Scholar
  6. [6]
    Atzpodien J, Korfer A, Evers P, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study. Mol Biother 2: 18–26.PubMedGoogle Scholar
  7. [7]
    Atzpodien J, Lopez HE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T (1995b) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497–501.PubMedGoogle Scholar
  8. [8]
    Atzpodien J, Poliwoda H, Kirchner H (1991) Alpha-Interferon and interleukin-2 in renal cell carcinoma: Studies in nonhospitalized patients. Semin Oncol 18: 108–112.PubMedGoogle Scholar
  9. [9]
    Aveta P, Terrone C, Neira D, Cracco C, Rocca RS (1997) Chemotherapy with FUDR in the management of metastatic renal cell carcinoma. Ann Urol (Paris) 31: 159–163.Google Scholar
  10. [10]
    Bakke A, Goethlin J, Hoisaeter PA (1985) Renal malignancies: Outcome of patients in stage 4 with or without embolization procedure. Urology 26: 541–543.PubMedGoogle Scholar
  11. [11]
    Balint I, Fischer J, Ljungberg B, Kovacs G (1999) Mapping the papillary renal cell carcinoma gene between loci D17S787 and D17S1799 on chromosome 17q21.32. Lab Invest 79: 1713–1718.PubMedGoogle Scholar
  12. [12]
    Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J (1995) Cytoreductive surgery for stage IV renal cell carcinoma [see Comments]. J Urol 154: 32–34.PubMedGoogle Scholar
  13. [13]
    Bentz M, Bergerheim US, Li C, Joos S, Werner CA, Baudis M, Gnarra J, Merino MJ, Zbar B, Linehan WM, Lichter P (1996) Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. Cytogenet Cell Genet 75: 17–21.PubMedGoogle Scholar
  14. [14]
    Berg WJ, Schwartz LH, Amsterdam A, Mazumdar M, Vlamis V, Law TM, Nanus DM, Motzer RJ (1997) A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15: 353–355.PubMedGoogle Scholar
  15. [15]
    Berlin J, King AC, Tutsch K, Findlay JW, Köhler P, Collier M, Clendeninn NJ, Wilding G (1994) A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs 12: 137–141.PubMedGoogle Scholar
  16. [16]
    Birnbaum BA, Jacobs JE, Ramchandani P (1996) Multiphasic renal CT: Comparison of renal mass enhancement during the corticomedullary and nephrographic phases. Radiology 200: 753–758.PubMedGoogle Scholar
  17. [17]
    Blacher E, Johnson DE, Haynie TP (1985) Value of routine radionuclide bone scans in renal cell carcinoma. Urology 26: 432–434.PubMedGoogle Scholar
  18. [18]
    Blackley SK, Ladaga L, Woolfitt RA, Schellhammer PF (1988) Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma. J Urol 140: 6–10.PubMedGoogle Scholar
  19. [19]
    Brandscheid D, Pomer S, Krysa S, Vogt-Moykopf I (1994) Survival after lung surgery for metastatic renal cancer. In: Staehler G, Pomer S (eds) Contemporary Research on Renal Cell Carcinoma. Springer, Heidelberg, S. 30–38.Google Scholar
  20. [20]
    Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, Decker HJ (2000) VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60: 1942–1948.PubMedGoogle Scholar
  21. [21]
    Bruntsch U, Heinrich B, Kaye SB, de Mulder PH, van Oosterom A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1064–1067.PubMedGoogle Scholar
  22. [22]
    Buer J, Probst M, Ganser A, Atzpodien J (1995) Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma [Letter]. J Clin Oncol 13: 2679–2680.PubMedGoogle Scholar
  23. [23]
    Bugert P, Gaul C, Weber K, Herbers J, Akhtar M, Ljungberg B, Kovacs G (1997) Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest 76: 203–208.PubMedGoogle Scholar
  24. [24]
    Bugert P, von Knobloch R, Kovacs G (1998) Duplication of two distinct regions on chromosome 5q in non-papillary renal-cell carcinomas. Int J Cancer 76: 337–340.PubMedGoogle Scholar
  25. [25]
    Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP (1990) Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A Southwest Oncology Group study. J Natl Cancer Inst 82: 143–146.PubMedGoogle Scholar
  26. [26]
    Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P, Sandstrom K, Tuason L, Rayman P, Tubbs R, McLain D, Klein E, Novick A, Finke J (1997) Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response. J Immunother 20: 301–311.PubMedGoogle Scholar
  27. [27]
    Buter J, Sleijfer DT, van der Graaf WT, de Vries EG, Willemse PH, Mulder NH (1993) A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 20: 16–21.PubMedGoogle Scholar
  28. [28]
    Buzio C, De Palma G, Passalacqua R, Potenzoni D, Ferrozzi F, Cattabiani MA, Manenti L, Borghetti A (1997) Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 76: 541–544.PubMedGoogle Scholar
  29. [29]
    Cairns P, Tokino K, Eby Y, Sidransky D (1995) Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55: 224–227.PubMedGoogle Scholar
  30. [30]
    Casali A, Sega FM, Casali M, Serrone L, Terzoli E (1998) 13-cis-Retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res 17:227–229.PubMedGoogle Scholar
  31. [31]
    Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S (1997) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15: 796–807.PubMedGoogle Scholar
  32. [32]
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192–3198.PubMedGoogle Scholar
  33. [33]
    Christensen K, Dyreborg U, Andersen JF, Nissen HM (1985) The value of transvascular embolization in the treatment of renal carcinoma. J Urol 133: 191–193.PubMedGoogle Scholar
  34. [34]
    Clark JI, Gaynor ER, Martone B, Budds SC, Manjunath R, Flanigan RC, Waters WB, Sosman JA (1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin Cancer Res 5: 2374–2380.PubMedGoogle Scholar
  35. [35]
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S (1990) Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res 50: 7343–7350.PubMedGoogle Scholar
  36. [36]
    Corless CL, Aburatani H, Fletcher JA, Housman DE, Amin MB, Weinberg DS (1996) Papillary renal cell carcinoma: Quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy. Diagn Mol Pathol 5: 53–64.PubMedGoogle Scholar
  37. [37]
    Couillard DR, de Vere White RW (1993) Surgery of renal cell carcinoma. Urol Clin North Am 20: 263–275.PubMedGoogle Scholar
  38. [38]
    de Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J (1996) Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491–495.PubMedGoogle Scholar
  39. [39]
    Dernevik L, Berggren H, Larsson S, Roberts D (1985) Surgical removal of pulmonary metastases from renal cell carcinoma. Scand J Urol Nephrol 19: 133–137.PubMedGoogle Scholar
  40. [40]
    Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4: 2729–2739.PubMedGoogle Scholar
  41. [41]
    Dreicer R, Smith DC, Williams RD, See WA (1999) Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 17: 183–186.PubMedGoogle Scholar
  42. [42]
    Duensing S, Dallmann I, Grosse J, Buer J, Lopez HE, Deckert M, Storkel S, Kirchner H, Poliwoda H, Atzpodien J (1994) Immunocytochemical detection of P-glycoprotein: Initial expression correlates with survival in renal cell carcinoma patients. Oncology 51:309–313.PubMedGoogle Scholar
  43. [43]
    Durrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, Thierry D, Gorter A, Hirsch R, Charpentier B, Senik A, Hirsch F (1999) Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 6: 564–571.PubMedGoogle Scholar
  44. [44]
    Einzig AI, Gorowski E, Sasloff J, Wiernik PH (1991) Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9: 133–136.PubMedGoogle Scholar
  45. [45]
    Elias L, Binder M, Mangalik A, Clark D, Morrison B, Altobelli KK, Smith A (1999) Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol 22: 156–161.PubMedGoogle Scholar
  46. [46]
    Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, Crawford ED (1996) A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer 78: 1085–1088.PubMedGoogle Scholar
  47. [47]
    Ellerhorst JA, Sell A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80: 2128–2132.PubMedGoogle Scholar
  48. [48]
    Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D (1996) Radical nephrectomy for renal cell carcinoma 30 mm or less: Long-term follow results. J Urol 155:1196–1199.PubMedGoogle Scholar
  49. [49]
    Facendola G, Locatelli MC, Pizzocaro G, Piva L, Pegoraro C, Pallavicini EB, Signaroldi A, Meregalli M, Lombardi F, Beretta GD (1995) Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: A confirmatory study. Br J Cancer 72: 1531–1535.PubMedGoogle Scholar
  50. [50]
    Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, de Kernion J, Belldegrun A (1997) Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients [see Comments]. Cancer J Sei Am 3Suppl 1: 92–97.Google Scholar
  51. [51]
    Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G (1998) Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17: 733–739.PubMedGoogle Scholar
  52. [52]
    Foon KA, Walther PJ, Bernstein ZP, Vaickus L, Rahman R, Watanabe H, Sweeney J, Park J, Vesper D, Russell D (1992) Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother 11: 184–190.PubMedGoogle Scholar
  53. [53]
    Fossa SD, Droz JP, Pavone-Macaluso MM, Debruyne FJ, Vermeylen K, Sylvester R (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A: 878–880.PubMedGoogle Scholar
  54. [54]
    Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J (1999) Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17: 529–533.PubMedGoogle Scholar
  55. [55]
    Frohmuller HG, Grups JW, Heller V (1987) Comparative value of ultrasonography, computerized tomography, angiography and excretory urography in the staging of renal cell carcinoma. J Urol 138: 482–484.PubMedGoogle Scholar
  56. [56]
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696.PubMedGoogle Scholar
  57. [57]
    Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1996) Longterm response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy [Letter]. J Clin Oncol 14: 2410–2411.PubMedGoogle Scholar
  58. [58]
    Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 77: 2560–2566.PubMedGoogle Scholar
  59. [59]
    Gebrosky NP, Koukol S, Nseyo UO, Carpenter C, Lamm DL (1997) Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. Urology 50: 863–867.PubMedGoogle Scholar
  60. [60]
    Geertsen PF, Hermann GG, Von der Maase H, Steven K (1992) Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study. J Clin Oncol 10: 753–759.PubMedGoogle Scholar
  61. [61]
    Gez E, Mekori T, Struminger L, Rubinov R, Nativ O, Stein A, Haim N, Kuten A (1999) T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine. Cancer Invest 17:259–263.PubMedGoogle Scholar
  62. [62]
    Glukhova L, Goguel AF, Chudoba I, Angevin E, Pavon C, Terrier-Lacombe MJ, Meddeb M, Escudier B, Bernheim A (1998) Overrepresentation of 7q31 and 17q in renal cell carcinomas. Genes Chromosomes Cancer 22: 171–178.PubMedGoogle Scholar
  63. [63]
    Glukhova L, Lavialle C, Fauvet D, Chudoba I, Danglot G, Angevin E, Bernheim A, Goguel AF (2000) Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: Increased copy number and overexpression of the MET proto-oncogene. Oncogene 19: 754–761.PubMedGoogle Scholar
  64. [64]
    Guida M, Latorre A, Mastria A (1992) Sc recombinant interleukin-2 treatment in metastatic renal cell cancer and melanoma. Ann Oncol 3[Suppl. 5]: 140.Google Scholar
  65. [65]
    Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A (1997) TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 992–993.PubMedGoogle Scholar
  66. [66]
    Harris RD, Goergen TG, Talner LB (1975) The bloody renal cyst aspirate: A diagnostic dilemma. J Urol 114: 832–835.PubMedGoogle Scholar
  67. [67]
    Hathorn RW, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C, de Kernion JB, Belldegrun A (1994) In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer 74: 1904–1911.PubMedGoogle Scholar
  68. [68]
    Hayakawa M, Hatano T, Tsuji A, Nakajima F, Ogawa Y (1996) Patients with renal cysts associated with renal cell carcinoma and the clinical implications of cyst puncture: A study of 223 cases. Urology 47: 643–646.PubMedGoogle Scholar
  69. [69]
    Herbers J, Schullerus D, Müller H, Kenck C, Chudek J, Weimer J, Bugert P, Kovacs G (1997) Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 19: 29–35.PubMedGoogle Scholar
  70. [70]
    Herrmann F (1996) Clinical application of gene transfer. J Mol Med 74: 213–221.PubMedGoogle Scholar
  71. [71]
    Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, inter-feron-alpha and 5-fluorouracil [see Comments]. J Urol 156: 18–21.PubMedGoogle Scholar
  72. [72]
    Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161: 777–782.PubMedGoogle Scholar
  73. [73]
    Hrushesky WJ, Murphy GP (1977) Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9: 277–288.PubMedGoogle Scholar
  74. [74]
    Hughson MD, Bigler S, Dickman K, Kovacs G (1999) Renal cell carcinoma of end-stage renal disease: An analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification. Mod Pathol 12: 301–309.PubMedGoogle Scholar
  75. [75]
    Hughson MD, Johnson LD, Silva FG, Kovacs G (1993) Nonpapillary and papillary renal cell carcinoma: A cytogenetic and phenotypic study. Mod Pathol 6: 449–456.PubMedGoogle Scholar
  76. [76]
    Huland E, Heinzer H, Huland H (1999) Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 19: 2679–2683.PubMedGoogle Scholar
  77. [77]
    Igarashi T, Marumo K, Onishi T, Kobayashi M, Aiba K, Tsushima T, Ozono S, Tomita Y, Terachi T, Satomi Y, Kawamura J (1999) Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: An open multicenter trial. The Japanese Study Group Against Renal Cancer. Urology 53: 53–59.PubMedGoogle Scholar
  78. [78]
    Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091–1097.PubMedGoogle Scholar
  79. [79]
    Jacobs A, Gold P, Weiden P, Aboulafia D, Rudolph R, Picozzi V, Thompson J (2000) Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Cancer Invest 18(5): 417–421.PubMedGoogle Scholar
  80. [80]
    Jaffee EM, Pardoll DM (1995) Gene therapy: Its potential applications in the treatment of renal-cell carcinoma. Semin Oncol 22: 81–91.PubMedGoogle Scholar
  81. [81]
    Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM (1996) Small (< or = 3 cm) renal masses: Detection with CT versus US and pathologic correlation [see Comments]. Radiology 198: 785–788.PubMedGoogle Scholar
  82. [82]
    Jayson GC, Middleton M, Lee SM, Ashcroft L, Thatcher N (1998) A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 78: 366–369.PubMedGoogle Scholar
  83. [83]
    Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PW, Whicher JT, Selby PJ (1996) A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation. Br J Urol 77: 638–649.PubMedGoogle Scholar
  84. [84]
    Johnson CD, Dunnick NR, Cohan RH, Illescas FF (1987) Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 148: 59–63.PubMedGoogle Scholar
  85. [85]
    Kaisary AV, Williams G, Riddle PR (1984) The role of preoperative embolization in renal cell carcinoma. J Urol 131: 641–646.PubMedGoogle Scholar
  86. [86]
    Karp SE (1998) Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma. J Immunother 21: 56–61.PubMedGoogle Scholar
  87. [87]
    Kenck C, Bugert P, Wilhelm M, Kovacs G (1997) Duplication of an approximately 1.5 Mb DNA segment at chromosome 5q22 indicates the locus of a new tumour gene in nonpapillary renal cell carcinomas. Oncogene 14: 1093–1098.PubMedGoogle Scholar
  88. [88]
    Khurana KK, Truong LD, Verani RR (1998) Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: Comparison with classic renal cell carcinoma. Mod Pathol 11: 339–346.PubMedGoogle Scholar
  89. [89]
    Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164: 1269–1276.PubMedGoogle Scholar
  90. [80]
    Kim EE, Bledin AG, Gutierrez C, Haynie TP (1983) Comparison of radionuclide images and radiographs for skeletal metastases from renal cell carcinoma. Oncology 40: 284–286.PubMedGoogle Scholar
  91. [91]
    Kirchner HH, Anton P, Atzpodien J (1995) Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 13: 171–173.PubMedGoogle Scholar
  92. [92]
    Kirman H, Bacon RL (1952) Estrogen-induced tumors of the kidney. I. Incidence of renal tumors in intact and gonadectomized male golden hamsters treated with diethyl-stilbestrol. Natl Cancer Inst 13: 745–755.Google Scholar
  93. [93]
    Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74: 916–919.PubMedGoogle Scholar
  94. [94]
    Kjaer M, Frederiksen PL, Engelholm SA (1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13: 665–672.PubMedGoogle Scholar
  95. [95]
    Kovacs A, Kovacs G (1992) Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosomes Cancer 4: 267–268.PubMedGoogle Scholar
  96. [96]
    Kovacs G (1989) Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol 134: 27–34.PubMedGoogle Scholar
  97. [97]
    Kovacs G, Emanuel A, Neumann HP, Kung HF (1991) Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer 3: 256–262.PubMedGoogle Scholar
  98. [98]
    Kovacs G, Frisch S (1989) Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas. Cancer Res 49: 651–659.PubMedGoogle Scholar
  99. [99]
    Kozak W, Holtl W, Pummer K, Maier U, Jeschke K, Bucher A (1996) Adrenalectomy — still a must in radical renal surgery? Br J Urol 77: 27–31.PubMedGoogle Scholar
  100. [100]
    Kozlowski JM (1994) Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am 21: 601–624.PubMedGoogle Scholar
  101. [101]
    Kügler A, Stuhler G, Waiden P, Zoller G, Zobywalski A, Brossait P, Tiefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kauz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6(3): 332–336.PubMedGoogle Scholar
  102. [102]
    Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998 [published errata appear in CA Cancer J Clin (1998) May-Jun 48(3): 192 and (1998) Nov-Dec 48(6): 329]. CA Cancer J Clin 48: 6–29.PubMedGoogle Scholar
  103. [103]
    Lang EK (1973) Roentgenographic assessment of asymptomatic renal lesions. An analysis of the confidence level of diagnoses established by sequential roentgenographic investigation. Radiology 109: 257–269.PubMedGoogle Scholar
  104. [104]
    Law TM, Ilson DH, Motzer RJ (1994b) Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12: 143–145.PubMedGoogle Scholar
  105. [105]
    Law TM, Mencel P, Motzer RJ (1994a) Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 12: 323–325.PubMedGoogle Scholar
  106. [106]
    Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of inter-leukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76: 824–832.PubMedGoogle Scholar
  107. [107]
    Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, Vaghi M, Tancini G (1992) Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28: 92–96.PubMedGoogle Scholar
  108. [108]
    Locatelli MC, Facendola G, Pizzocaro G, Piva L, Pegoraro C, Pallavicini EB, Signaroldi A, Meregalli M, Lombardi F, Beretta GD, Scanzi F, Labianca R, Dallavalle G, Luporini G (1999) Subcutaneous administration of interleukin-2 and interferon-alpha 2b in advanced renal cell carcinoma: Long-term results. Cancer Detect Prev 23: 172–176.PubMedGoogle Scholar
  109. [109]
    Lopez-Hanninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155: 19–25.PubMedGoogle Scholar
  110. [110]
    Lopez M, Carpano S, Cancrini A, Marcellini M, Del Medico P, Rinaldi M, Vici P, Paoletti G, Di Lauro L (1993) Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma. Ann Oncol 4:689–691.PubMedGoogle Scholar
  111. [111]
    Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191: 795–804.PubMedGoogle Scholar
  112. [112]
    Lummen G, Sperling H, Luboldt H, Otto T, Rubben H (1998) Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42: 415–417.PubMedGoogle Scholar
  113. [113]
    MacDougall ML, Welling LW, Wiegmann TB (1987) Renal adenocarcinoma and acquired cystic disease in chronic hemodialysis patients. Am J Kidney Dis 9: 166–171.PubMedGoogle Scholar
  114. [114]
    Maldazys JD, de Kernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136: 376–379.PubMedGoogle Scholar
  115. [115]
    Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993) Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet 65: 1–6.PubMedGoogle Scholar
  116. [116]
    Mickisch GH, Noordzij MA, Gaast A, Gebreamlack P, Kohrmann KU, Mogler-Drautz E, Küpper H, Schroder FH (1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121Suppl 3: R11–R16.PubMedGoogle Scholar
  117. [117]
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281.PubMedGoogle Scholar
  118. [118]
    Moch H, Presti Jr. JC, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM (1996) Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56: 27–30.PubMedGoogle Scholar
  119. [119]
    Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma [see Comments]. N Engl J Med 335: 865–875.PubMedGoogle Scholar
  120. [120]
    Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O’Brien JP (1995b) Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958–1965.PubMedGoogle Scholar
  121. [121]
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540.PubMedGoogle Scholar
  122. [122]
    Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4: 1183–1191.PubMedGoogle Scholar
  123. [123]
    Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM (1995a) Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950–1957.PubMedGoogle Scholar
  124. [124]
    Mukamel E, Konichezky M, Engelstein D, Servadio C (1988) Incidental small renal tumors accompanying clinically overt renal cell carcinoma. J Urol 140: 22–24.PubMedGoogle Scholar
  125. [125]
    Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ (1994) A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am J Clin Oncol 17: 10–13.PubMedGoogle Scholar
  126. [126]
    Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, Seliger B (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies? Cancer Res 58: 4090–4095.PubMedGoogle Scholar
  127. [127]
    Nguyen BD, Westra WH, Zerhouni EA (1996) Renal cell carcinoma and tumor thrombus neovascularity: MR demonstration with pathologic correlation. Abdom Imaging 21: 269–271.PubMedGoogle Scholar
  128. [128]
    Nieken J, Mulder NH, Pietens J, Limburg PC, de Leij L, de Vries EG (1999) The modulatory impact of recombinant human interleukin-6 on the immune system of cancer patients. J Immunother 22: 363–370.PubMedGoogle Scholar
  129. [129]
    Novick AC (1995) Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. Semin Oncol 22: 29–33.PubMedGoogle Scholar
  130. [130]
    O’dea MJ, Zincke H, Utz DC, Bernatz PE (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120: 540–542.Google Scholar
  131. [131]
    Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, Kirchner H, Atzpodien J (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83[5] (in press).Google Scholar
  132. [132]
    Oleksowicz L, Dutcher JP (1999) A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 125: 101–108.PubMedGoogle Scholar
  133. [133]
    Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8: 1630–1636.PubMedGoogle Scholar
  134. [134]
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain [see Comments]. N Engl J Med 322: 494–500.PubMedGoogle Scholar
  135. [135]
    Pectasides D, Varthalitis J, Kostopoulou M, Mylonakis A, Triantaphyllis D, Papadopoulou M, Dimitriadis M, Athanassiou A (1998) An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 55: 10–15.PubMedGoogle Scholar
  136. [136]
    Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR (1991) Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study. J Immunother 10: 57–62.PubMedGoogle Scholar
  137. [137]
    Pierce WC, Belldegrun A, Figlin RA (1995) Cellular therapy: Scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol 22: 74–80.PubMedGoogle Scholar
  138. [138]
    Piga A, Giordani P, Quattrone A, Giulioni M, De Signoribus G, Antognoli S, Cellerino R (1997) A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma. Cancer Immunol Immunother 44: 348–351.PubMedGoogle Scholar
  139. [139]
    Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontaneila U, Longo G (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138: 1379–1381.PubMedGoogle Scholar
  140. [140]
    Porena M, Vespasiani G, Rosi P, Costantini E, Virgili G, Mearini E, Micali F (1992) Incidentally detected renal cell carcinoma: Role of ultrasonography. J Clin Ultra-sound 20: 395–400.Google Scholar
  141. [141]
    Prati GF, Saggin P, Boschiero L, Martini PT, Montemezzi S, Muolo A (1993) Small renal-cell carcinomas: Clinical and imaging features. Urol Int 51: 19–22.PubMedGoogle Scholar
  142. [142]
    Probst M, Buer J, Atzpodien J (1995) Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma [Letter; Comment]. Lancet 345: 723–724.PubMedGoogle Scholar
  143. [143]
    Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W (1996) Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87: 4333–4339.PubMedGoogle Scholar
  144. [144]
    Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D (1994) The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152: 1399–1403.PubMedGoogle Scholar
  145. [145]
    Rackley RR, Klein EA, Novick A (1991) Morbidity and mortality of primary adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 144: 422.Google Scholar
  146. [146]
    Ratain MJ, Priest ER, Janisch L, Vogelzang NJ (1993) A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 71: 2371–2376.PubMedGoogle Scholar
  147. [147]
    Ravaud A, Negrier S, Cany L, Merrouche Y, Le Guillou M, Blay JY, Clavel M, Gaston R, Oskam R, Philip T (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma [published erratum appears in Br J Cancer (1994) Dec 70(6): 1284]. Br J Cancer 69: 1111–1114.PubMedGoogle Scholar
  148. [148]
    Reese DM, Corry M, Small EJ (2000) Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma [in process citation]. Cancer 88: 1310–1316.PubMedGoogle Scholar
  149. [149]
    Renshaw AA, Corless CL (1995) Papillary renal cell carcinoma. Histology and immunohistochemistry. Am J Surg Pathol 19: 842–849.PubMedGoogle Scholar
  150. [150]
    Rigos D, Wechsel HW, Bichler KH (1999) Treosulfan in the treatment of metastatic renal cell carcinoma. Anticancer Res 19: 1549–1552.PubMedGoogle Scholar
  151. [151]
    Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ (1998) Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: A phase II trial. Cancer 82: 1352–1358.PubMedGoogle Scholar
  152. [152]
    Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Berman A, Merino M, Rosenberg SA (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144: 614–617.PubMedGoogle Scholar
  153. [153]
    Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301.PubMedGoogle Scholar
  154. [154]
    Rosen PR, Murphy KG (1984) Bone scintigraphy in the initial staging of patients with renal-cell carcinoma: Concise communication. J Nucl Med 25: 289–291.PubMedGoogle Scholar
  155. [155]
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492.PubMedGoogle Scholar
  156. [156]
    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J Natl Cancer Inst (1993) Jul 7 85(13): 1091]. J Natl Cancer Inst 85: 622–632.PubMedGoogle Scholar
  157. [157]
    Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see Comments]. JAMA 271: 907–913.PubMedGoogle Scholar
  158. [158]
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM (2000) Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: Results of two phase II clinical trials [in process citation]. Cancer 88: 1317–1324.PubMedGoogle Scholar
  159. [159]
    Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL (1997) Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A cancer and leukemia group B study. Clin Cancer Res 3:1977–1984.PubMedGoogle Scholar
  160. [160]
    Sandock DS, Seftel AD, Resnick Ml (1995) A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 154: 28–31.PubMedGoogle Scholar
  161. [161]
    Savage PD (1995) Renal cell carcinoma. Curr Opin Oncol 7: 275–280.PubMedGoogle Scholar
  162. [162]
    Savage PD, Muss HB (1995) Renal cell cancer. In: Devita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer. J. B. Lippincott, Philadelphia, S. 373–387.Google Scholar
  163. [163]
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM (1996) Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: A phase IB study. Clin Cancer Res 2: 319–330.PubMedGoogle Scholar
  164. [164]
    Schlehofer B, Pommer W, Mellemgaard A, Stewart JH, McCredie M, Niwa S, Lindblad P, Mandel JS, McLaughlin JK, Wahrendorf J (1996) International renal-cell-cancer study. VI. The role of medical and family history. Int J Cancer 66: 723–726.PubMedGoogle Scholar
  165. [165]
    Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73.PubMedGoogle Scholar
  166. [166]
    Schraml P, Müller D, Bednar R, Gasser T, Sauter G, Mihatsch MJ, Moch H (2000) Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J Pathol 190: 457–461.PubMedGoogle Scholar
  167. [167]
    Schüler M, Bruntsch U, Spath-Schwalbe E, Schrezenmeier H, Peschel C, Farber L, Burger KJ, Leissner J, Huber C, Aulitzky WE (1998) Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study. Eur J Cancer 34: 754–756.PubMedGoogle Scholar
  168. [168]
    Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G (1997) Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of nonpapillary renal cell carcinomas. J Pathol 183: 151–155.PubMedGoogle Scholar
  169. [169]
    Schullerus D, von Knobloch R, Chudek J, Herbers J, Kovacs G (1999) Microsatellite analysis reveals deletion of a large region at chromosome 8p in conventional renal cell carcinoma. Int J Cancer 80: 22–24.PubMedGoogle Scholar
  170. [170]
    Schwartsmann G, Medina C, Silveira LA, Salgado G, Thereza MS, Vinholes J, Preger P, Segal F (1991) Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group [Letter]. Ann Oncol 2: 443.PubMedGoogle Scholar
  171. [171]
    Schwerdtle RF, Storkel S, Neuhaus C, Brauch H, Weidt E, Brenner W, Hohenfellner R, Huber C, Decker HJ (1996) Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma [retracted by Schwerdtle RF, Neuhaus C, Weidt E, Huber C, Brenner W, Hohenfellner R, Winterpacht A, Zabel B, Decker HJ, Storkel S, Brauch H (1999) Cancer Res 59(8): 2021]. Cancer Res 56: 2927–2930.PubMedGoogle Scholar
  172. [172]
    SCI AM: Fact sheet (1996) Twelve major cancers. Sci Am 275: 126–132.Google Scholar
  173. [173]
    Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ (1994) Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9: 103–111.PubMedGoogle Scholar
  174. [174]
    Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM (1993) Renal cancer staging: Comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 3: 597–602.PubMedGoogle Scholar
  175. [175]
    Soori GS, Schulof RS, Stark JJ, Wiemann MC, Honeycutt PJ, Church CK, De Priest CB (1999) Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: A national biotherapy study group phase II study [see Comments]. Cancer Invest 17: 379–384.PubMedGoogle Scholar
  176. [176]
    Speicher MR, Schoell B, Du MS, Schrock E, Ried T, Cremer T, Storkel S, Kovacs A, Kovacs G (1994) Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 145: 356–364.PubMedGoogle Scholar
  177. [177]
    Stadler WM, Kuzel T, Dumas M, Vogelzang NJ (1998) Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 16: 1820–1825.PubMedGoogle Scholar
  178. [178]
    Stadler WM, Rybak ME, Vogelzang NJ (1995) A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 76: 1629–1633.PubMedGoogle Scholar
  179. [179]
    Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E (1999a) Phase I radioimmunotherapy of metastatic renal cell carcinoma with 1311—labeled chimeric monoclonal antibody G250. Clin Cancer Res 5: 3268s–3274s.PubMedGoogle Scholar
  180. [180]
    Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC (1999b) In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. J Nucl Med 40: 829–836.PubMedGoogle Scholar
  181. [181]
    Steger GG, Kaboo R, de Kernion JB, Figlin R, Belldegrun A (1995) The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma. Br J Cancer 72: 101–107.PubMedGoogle Scholar
  182. [182]
    Steinbach F, Stockle M, Hohenfellner R (1995) Current controversies in nephronsparing surgery for renal-cell carcinoma. World J Urol 13: 163–165.PubMedGoogle Scholar
  183. [183]
    Stief CG, Schafers HJ, Kuczyk M, Anton P, Pethig K, Truss MC, Jonas U (1995) Renal-cell carcinoma with intracaval neoplastic extension: Stratification and surgical technique. World J Urol 13: 166–170.PubMedGoogle Scholar
  184. [184]
    Storkel S (1999) Epithelial tumors of the kidney. Pathological subtyping and cytogenetic correlation. Urologe A38: 425–432.Google Scholar
  185. [185]
    Storkel S, van den Berg E (1995) Morphological classification of renal cancer. World J Urol 13: 153–158.PubMedGoogle Scholar
  186. [186]
    Stouthard JM, Goey H, de Vries EG, de Mulder PH, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJ, Veenhof CH (1996) Recombinant human interleukin-6 in metastatic renal cell cancer: A phase II trial. Br J Cancer 73: 789–793.PubMedGoogle Scholar
  187. [187]
    Strander H, Mogensen KE, Cantell K (1975) Production of human lymphoblastoid interferon. J Clin Microbiol 1: 116–117.PubMedGoogle Scholar
  188. [188]
    Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ (1990) Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 144: 243–245.PubMedGoogle Scholar
  189. [189]
    Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19: 184–191.PubMedGoogle Scholar
  190. [190]
    Swanson DA, Johnson DE, von Eschenbach AC, Chuang VP, Wallace S (1983) Angioinfarction plus nephrectomy for metastatic renal ceil carcinoma — An update. J Urol 130: 449–452.PubMedGoogle Scholar
  191. [191]
    Sweeney JP, Thornhill JA, Graiger R, McDermott TE, Butler MR (1996) Incidentally detected renal cell carcinoma: Pathological features, survival trends and implications for treatment [see Comments]. Br J Urol 78: 351–353.PubMedGoogle Scholar
  192. [192]
    Tammela TL, Leinonen AS, Kontturi MJ (1991) Comparison of excretory urography, angiography, ultrasound and computed tomography for T category staging of renal cell carcinoma. Scand J Urol Nephrol 25: 283–286.PubMedGoogle Scholar
  193. [193]
    Taneja SS, Pierce W, Figlin R, Belldegrun A (1995) Immunotherapy for renal cell carcinoma: The era of interleukin-2-based treatment. Urology 45: 911–924.PubMedGoogle Scholar
  194. [194]
    Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush Jr WH, Benz LA, Fefer A (1992) Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 10: 960–968.PubMedGoogle Scholar
  195. [195]
    Thurnher M, Rieser C, Holtl L, Papesh C, Ramoner R, Bartsch G (1998) Dendritic cell-based immunotherapy of renal cell carcinoma. Urol Int 61: 67–71.PubMedGoogle Scholar
  196. [196]
    Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick RW, Skorecki KL, Warner E (1995) Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1: 1611–1615.PubMedGoogle Scholar
  197. [197]
    Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K (1998) Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: Long-term results. Int J Urol 5: 16–21.PubMedGoogle Scholar
  198. [198]
    Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 16: 2505–2513.PubMedGoogle Scholar
  199. [199]
    Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163: 1090–1095.PubMedGoogle Scholar
  200. [200]
    Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E (1999) MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81: 741–746.PubMedGoogle Scholar
  201. [201]
    van den Berg E, Dijkhuizen T, Oosterhuis JW, Geurts VK, de Jong B, Storkel S (1997) Cytogenetic classification of renal cell cancer. Cancer Genet Cytogenet 95: 103–107.PubMedGoogle Scholar
  202. [202]
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, de Mulder PH (2000) Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 82: 772–776.PubMedGoogle Scholar
  203. [203]
    Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11: 1809–1816.PubMedGoogle Scholar
  204. [204]
    Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE (1998) Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res 4: 929–934.PubMedGoogle Scholar
  205. [205]
    Von der Maase H, Geertsen P, Thatcher N, Jasmin C, Mercatello A, Fossa SD, Symann M, Stoter G, Nagel G, Israel L (1991) Recombinant interleukin-2 in metastatic renal cell carcinoma — A European multicentre phase II study. Eur J Cancer 27: 1583–1589.PubMedGoogle Scholar
  206. [206]
    von Knobloch R, Bugert P, Jauch A, Kalble T, Kovacs G (2000) Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J Pathol 190: 163–168.Google Scholar
  207. [207]
    Walter TA, Berger CS, Sandberg AA (1989) The cytogenetics of renal tumors. Where do we stand, where do we go? Cancer Genet Cytogenet 43: 15–34.PubMedGoogle Scholar
  208. [208]
    Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, Linehan WM, Rosenberg SA (1993) Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42: 250–257.PubMedGoogle Scholar
  209. [209]
    Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J, Skorecki KL (1995) Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 18:251–256.PubMedGoogle Scholar
  210. [210]
    Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL (1993) Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 53: 4745–4749.PubMedGoogle Scholar
  211. [211]
    Weiselberg L, Budman D, Vinciguerra V, Schulman P, Degnan TJ (1981) Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature. Cancer Clin Trials 4: 195–198.PubMedGoogle Scholar
  212. [212]
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10: 275–281.PubMedGoogle Scholar
  213. [213]
    Werf-Messing B v d (1973) Proceedings: Carcinoma of the kidney. Cancer 32: 1056–1061.PubMedGoogle Scholar
  214. [214]
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905.PubMedGoogle Scholar
  215. [215]
    Weterman MA, Wilbrink M, Geurts VK (1996a) Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 93: 15294–15298.PubMedGoogle Scholar
  216. [216]
    Weterman MA, Wilbrink M, Janssen I, Janssen HA, van den BE, Fisher SE, Craig I, Geurts VK (1996b) Molecular cloning of the papillary renal cell carcinoma-associated translocation (X;1)(p11;q21) breakpoint. Cytogenet Cell Genet 75: 2–6.PubMedGoogle Scholar
  217. [217]
    Whitmore Jr WF (1989) Renal cell carcinoma. Overview. Semin Urol 7: 271–273.Google Scholar
  218. [218]
    Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, Atzpodien J (1999) Interleukin 10 (IL-10): An immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 79: 1182–1184.PubMedGoogle Scholar
  219. [219]
    Wos E, Olencki T, Tuason L, Budd GT, Peereboom D, Sandstrom K, McLain D, Finke J, Bukowski RM (1996) Phase II trial of subcutaneously administered granu-locyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer 77: 1149–1153.PubMedGoogle Scholar
  220. [220]
    Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22: 42–60.PubMedGoogle Scholar
  221. [221]
    Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S (1998) Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 2: 57–60.PubMedGoogle Scholar
  222. [222]
    Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI (1994) Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12: 1572–1576.PubMedGoogle Scholar
  223. [223]
    Yang ZQ, Yoshida MA, Fukuda Y, Kurihara N, Nakamura Y, Inazawa J (2000) Molecular cytogenetic analysis of 17 renal cancer cell lines: Increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas. Jpn J Cancer Res 91: 156–163.PubMedGoogle Scholar
  224. [224]
    Zbar B, Brauch H, Talmadge C, Linehan M (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327: 721–724.PubMedGoogle Scholar
  225. [225]
    Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM (1994) Hereditary papillary renal cell carcinoma. J Urol 151: 561–566.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • Jens Atzpodien
    • 1
  • Tatjana Patzelt
    • 1
  • Martina Reitz
    • 1
  1. 1.Europäisches Institut für Tumor-Immunologie und Prävention (EUTIP)BonnDeutschland

Personalised recommendations